Overall and progression-free survival with everolimus, temsirolimus, or sorafenib as second targeted therapies for metastatic renal cell carcinoma: A retrospective U.S. chart review.
Hongbo Yang
Employment or Leadership Position - Analysis Group
Consultant or Advisory Role - Novartis
Michael K.K. Wong
Consultant or Advisory Role - Merck; Novartis; Pfizer
Honoraria - Merck; Novartis; Pfizer
James E. Signorovitch
Employment or Leadership Position - Analysis Group
Consultant or Advisory Role - Novartis
Xufang Wang
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
Zhimei Liu
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
Nathan S. Liu
Employment or Leadership Position - Analysis Group
Consultant or Advisory Role - Novartis
Zhengyun Qi
Employment or Leadership Position - Analysis Group
Consultant or Advisory Role - Novartis
Daniel J. George
Consultant or Advisory Role - Bayer; Novartis; Pfizer
Honoraria - Novartis; Pfizer
Research Funding - Novartis; Pfizer